Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) beyond progression in hormone receptor positive advanced breast cancer: a systematic review and meta-analysis

被引：0
|
作者：
Pathak, Neha
Kumar, Sudhir
Gimenez, Diego Malon
Di Iorio, Massimo
Valiente, Consolacion Molto
Cuthbert, Danielle
Li, Meredith
Batra, Atul
Nadler, Michelle
Amir, Eitan
Mittal, Abhenil
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO5-04-11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO5-04-11
引用
收藏
页数：3
相关论文
共 50 条
  • [1] The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC)
    Eiger, Daniel
    Wagner, Marcio
    Ponde, Noam F.
    Nogueira, Melanie S.
    Buisseret, Laurence
    de Azambuja, Evandro
    ACTA ONCOLOGICA, 2020, 59 (06) : 723 - 725
  • [2] Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them
    Foffano, L.
    Cucciniello, L.
    Nicolo, E.
    Migliaccio, I.
    Noto, C.
    Reduzzi, C.
    Malorni, L.
    Cristofanilli, M.
    Gerratana, L.
    Puglisi, F.
    Pitigliani, Sandro
    BREAST, 2025, 79
  • [3] A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer
    Zhang, Jialin
    Xu, Xinyu
    Zhou, Yeyue
    Su, Jingyang
    Wang, Jue
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [4] Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer
    Hecht, Keith A.
    Selby, Christopher
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (02) : 195 - 203
  • [5] Efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive breast cancer: a systematic review and meta-analysis
    Ergun, Yakup
    Dogan, Mutlu
    Ucar, Gokhan
    Karacin, Pinar
    Karacin, Cengiz
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (17) : 1901 - 1909
  • [6] Real world quality of life (QoL) in breast cancer (BC) patients treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i)
    Tavara, B. I.
    Garrido, M. L.
    Lopez, L.
    Lopez Flores, M.
    Castanon, C.
    Abella Alvarez, S.
    Medina Valdivieso, S.
    Rodriguez Sanchez, A.
    Garcia Palomo-Perez, A.
    Lopez, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S361 - S361
  • [7] Whole exome sequencing (WES) in hormone-receptor positive (HR plus ) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i).
    Wander, Seth Andrew
    Cohen, Ofir
    Johnson, Gabriela N.
    Kim, Dewey
    Luo, Flora
    Mao, Pingping
    Nayar, Utthara
    Helvie, Karla
    Marini, Lori
    Freeman, Samuel
    Getz, Gad
    Garraway, Levi A.
    Winer, Eric P.
    Lin, Nancy U.
    Wagle, Nikhil
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Relative risk of hepatotoxicity associated with cyclin-dependent kinase inhibitors (CDK4/6i): A systematic review and meta-analysis of phase 3 randomized controlled trials.
    Jahan, Nusrat
    Wongsaengsak, Sariya
    Rehman, Shabnam
    Adhikari, Nimesh
    Tijani, Lukman Aderoju
    Raghunath, Arrvind
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] CDK4/6 Inhibitors for Advanced Hormone Receptor-Positive Breast Cancer, 2019 and Beyond
    Layman, Rachel M.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (02): : 190 - 192
  • [10] Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging
    Graf, F.
    Mosch, B.
    Koehler, L.
    Bergmann, R.
    Wuest, F.
    Pietzsch, J.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2010, 10 (06) : 527 - 539
12345